The results confirmed the HemSC as a rare CD133+ subset comprising approximately 1% of the tumor cell population, with an ability to self-renew, multipotential ability to give rise to several cellular lineages with distinct morphologies and gene expression profiles, and a potential to regenerate GLUT1+ tumorspheres containing the HemSC and the differentiated derivatives (pericytes). The gene discussed is SLC2A1; the disease is neoplasm.